BIOVERIS CORP Form 8-K September 07, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 6, 2005

BIOVERIS CORPORATION

(Exact name of Registrant as specified in its charter)

Delaware000-5058380-0076765(State or Other Jurisdiction
of Incorporation)(Commission
File Number)(I.R.S. Employer
Identification No.)

16020 Industrial Drive20877Gaithersburg, MD(Zip Code)

(Address of Principal Executive Offices)

(301) 869-9800 (Registrant s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

" Written

communications

pursuant to

Rule 425 under

the Securities

Act (17 CFR

230.425)

" Soliciting

material

pursuant to

Rule 14a-12

under the

Exchange Act

(17 CFR

240.14a-12)

" Pre-commencement

communications

pursuant to

Rule 14d-2(b)

under the Exchange

Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On September 6, 2005, BioVeris Corporation (the Company) announced that it entered into a license agreement with The Rockefeller University. See the attached Press Release of the Company, dated September 6, 2005, filed herewith as Exhibit 99.1.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 7, 2005 BIOVERIS CORPORATION

By: /s/ George V. Migausky
Name: George V. Migausky

Title: Vice President of Finance and Chief

Financial Officer

EXHIBIT INDEX

Exhibit 99.1 Press Release of the Company, dated September 6, 2005.